通过调节STAT3通路,ANXA9促进S100A4并促进乳腺癌的进展
Xiqian Zhou1, Junyong Zhao1, Tao Yan1
1Department of Breast and Thyroid Surgery, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China.
Cell death & disease
|April 12, 2024
概括
附件A9 (ANXA9) 促进乳腺癌的进展和转移. 下调ANXA9抑制瘤生长和扩散,这表明ANXA9是转移性乳腺癌的治疗点.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 乳腺癌在全球的发病率和死亡率都很高.
- 异常的Annexin家族表达与恶性瘤有关,在乳腺癌中ANXA9上调.
- ANXA9的表达与乳腺癌的进展相关,特别是在转移性病例中.
研究的目的:
- 研究ANXA9在乳腺癌进展和转移中的作用.
- 阐明ANXA9在乳腺癌中的功能背后的分子机制.
- 评估ANXA9作为转移性乳腺癌的潜在治疗点.
主要方法:
- 在转移性乳腺癌组织中分析ANXA9表达.
- 在体外功能测试评估ANXA9对癌细胞增殖,运动,入侵和亡的影响.
- 在体内研究涉及乳腺癌异种移植模型中ANXA9的下调.
- 探讨ANXA9与S100A4的相互作用及其对信号通路 (AKT/mTOR/STAT3) 和细胞因子分泌 (IL-6,IL-8,CCL2,CCL5) 的影响的机制研究.
主要成果:
- 在转移性乳腺癌组织中发现高度表达的ANXA9,与疾病进展相关.
- 在实验室中,ANXA9影响了乳腺癌细胞的增殖,运动,入侵和亡.
- 抑制ANXA9的下调抑制了瘤生长和肺转移 in vivo.
- ANXA9调解S100A4,调节AKT/mTOR/STAT3通路,影响细胞亡,并通过细胞因子分泌和自我酸化促进血管生成.
结论:
- ANXA9在促进乳腺癌进展和转移方面发挥着重要作用.
- 向ANXA9可能是治疗转移性乳腺癌的可行的治疗策略.
相关概念视频
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
02:23Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
01:20The JAK-STAT Signaling Pathway
8.8K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.8K
01:22PI3K/mTOR/AKT Signaling Pathway
3.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.5K
02:07Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
01:16TGF - β Signaling Pathway
7.3K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.3K